What question did this study set out to answer?

To outline strategies and recent updates regarding the prevention and treatment of venous thromboembolism in adult patients with confirmed or suspected cancer.

November 1, 2018Journal of the National Comprehensive Cancer NetworkOpen Access

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

View Full Paper

Ask AI

Bookmark

Population

Adult patients diagnosed with cancer or in whom cancer is clinically suspected

Design

Guideline

Authors

MSMichael B. StreiffVascular Medicine BHBjorn HolmstromMoffitt Cancer Center DADana E. AngeliniCleveland Clinic

Discussion

Member takes

Implication

Updated NCCN anticoagulant recommendations for cancer-associated VTE merit review; leaves open optimal agent selection by cancer type.

Key Points

To outline strategies and recent updates regarding the prevention and treatment of venous thromboembolism in adult patients with confirmed or suspected cancer.
Expert consensus and clinical guideline development by the National Comprehensive Cancer Network panel.
Targeted focus on adult oncology patients needing venous thromboembolism prophylaxis or active therapy.
Provides updated recommendations regarding anticoagulant agent selection for treating cancer-associated venous thromboembolism.
Summarizes refined clinical strategies to address the complex balance between bleeding risk and thrombosis prevention in oncology.

Structured PICO

Population

Adult patients diagnosed with cancer or in whom cancer is clinically suspected

Intervention

Strategies for treatment and prevention of VTE, including recent changes in anticoagulants

The NCCN Guidelines Insights provide updated recommendations on the use of anticoagulants for managing cancer-associated venous thromboembolic disease.

Cite This Study

Streiff et al. (2018) studied this question.

synapsesocial.com/papers/6a7d1aefade38b7dc346cebe https://doi.org/10.6004/jnccn.2018.0084

View Full Paper

Ask AI

Bookmark

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider